Key result
Cardiovascular–kidney–metabolic syndrome affects ~90% of Mexican adults, driven predominantly by stage 2 disease.
Why the study?
The national distribution and population burden of cardiovascular-kidney-metabolic (CKM) stages among adults in Mexico were unknown.
Cross-Sectional (n=10,522)
Yes
Nearly 90% of Mexican adults (73.58 million people) meet criteria for CKM syndrome—with 60.8% in stage 2 and high prevalence already present in young adults aged 20–44 years—highlighting an urgent need for integrated cardiovascular, kidney, and metabolic prevention in Mexico.
Answers are grounded in this paper and cite their sources.
Signals large CKM burden in Mexican adults; extends staging framework to Latin American populations and leaves open intervention effects.
Background The cardiovascular–kidney–metabolic (CKM) framework integrates adiposity, metabolic risk factors, kidney disease, and cardiovascular disease into progressive stages. However, the national distribution and population burden of CKM stages in Mexico are unknown. We estimated the prevalence and corresponding population size of each CKM stage among Mexican adults. Methods We conducted a cross-sectional analysis of the 2018–2019 Mexican National Health and Nutrition Survey. The analytical sample included 10,522 adults aged ≥ 20 years from the fasting serum subsample. Participants were classified into mutually exclusive CKM stages 0–4 using a hierarchical algorithm based on the current CKM staging framework and adapted to the survey variables available. Classification incorporated anthropometry, glycaemia, blood pressure, lipids, estimated glomerular filtration rate, PREVENT-CVD risk, and self-reported clinical cardiovascular disease. Survey weights were recalibrated to national population margins, and design-based prevalence estimates, 95% confidence intervals, and population counts were calculated. Results The analytical sample represented 82.16 million Mexican adults. Stage 2 was the most prevalent category, affecting 60.8% (95% CI 59.2–62.4%), or approximately 49.95 million adults. The prevalences of stages 0, 1, 3, and 4 were 10.4%, 21.3%, 3.7%, and 3.8%, respectively. Overall, 89.6% (95% CI 88.5–90.6%), representing 73.58 million adults, met criteria for CKM stages 1–4, while advanced CKM syndrome (stages 3–4) affected 7.5% (6.6–8.3%), or 6.13 million. Among adults aged 20–44 years, 83.7% had CKM stages 1–4 and 54.1% were already in stage 2. Allowing triglycerides ≥ 150 mg/dL to independently qualify for stage 2 increased its prevalence to 69.1%, whereas the prevalence of any CKM syndrome increased more modestly to 91.8%. Conclusions Nearly nine in ten Mexican adults met criteria for CKM syndrome, with the burden concentrated in stage 2 and already evident in early adulthood. These estimates identify substantial population needs for integrated metabolic, kidney, and cardiovascular prevention and provide a national baseline for CKM surveillance and health-system planning in Mexico.
No takes yet. Share an insight, caveat, or question.
Silva-Tinoco et al. (2026) conducted a cross-sectional in Cardiovascular-kidney-metabolic (CKM) syndrome (n=10,522). Operational cardiovascular–kidney–metabolic (CKM) syndrome staging framework (Stages 0–4) vs. Operational Stage 0 (absence of CKM risk factors) was evaluated on Prevalence of any CKM syndrome (Stages 1–4) among Mexican adults (95% CI 88.5-90.6). Cardiovascular–kidney–metabolic syndrome (stages 1–4) affected 89.6% (95% CI 88.5–90.6%) of Mexican adults, with stage 2 being most prevalent at 60.8% (95% CI 59.2–62.4%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: